| Code | CSB-RA011614MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to AVTX-009, targeting interleukin-1 beta (IL-1β), a potent pro-inflammatory cytokine central to innate immune responses. IL-1β plays a critical role in initiating and amplifying inflammatory cascades by promoting fever, activating endothelial cells, and stimulating the production of additional inflammatory mediators. Dysregulated IL-1β signaling is implicated in numerous pathological conditions, including autoinflammatory diseases, rheumatoid arthritis, type 2 diabetes, cardiovascular disease, and various malignancies where chronic inflammation contributes to tumor progression and therapeutic resistance.
AVTX-009 is a humanized monoclonal antibody targeting IL-1β. By neutralizing IL-1β, AVTX-009 aims to alleviate tissue inflammation, relieve pain and improve tissue damage, and is being explored for the treatment of moderate to severe suppurative apocrineitis. This biosimilar provides researchers with a valuable tool for investigating IL-1β-mediated pathways, evaluating inflammatory disease models, and exploring the therapeutic potential of IL-1β blockade across diverse research contexts. The antibody enables detailed mechanistic studies of cytokine signaling, inflammation resolution, and immune cell activation, supporting translational research efforts in immunology, oncology, and metabolic disease.
There are currently no reviews for this product.